Trial Profile
A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Clinical Activity of ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Leigh disease
- Focus Adverse reactions
- Sponsors AADi; Aadi Bioscience
- 18 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Sep 2021 Planned initiation date changed from 31 Aug 2021 to 30 Apr 2022.
- 17 Mar 2021 Planned initiation date changed from 1 Mar 2021 to 31 Aug 2021.